Faculty

Institution

Unit

Venue

Carol Beadling

Oregon Health & Science University

Affiliations

OHSU School of Medicine

Department Of Medicine

Department Of Pediatrics

Department of Medicine

Division of Hematology & Medical Oncology

Department Of Medicine

Hematology and Medical Oncology

Department Of Pediatrics

Hematology and Oncology

Oregon Health & Science University

NoneCarol Beadling is currently serving as a Medicine faculty at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Carol Beadling

Oregon Health & Science University

You can click a keyword to filter the displayed items

pathology oncology cancer research genetics oncogenes cancer genetics tumor biology molecular diagnostics cancer genomics cancer biology molecular biology molecular cancer immunology breast cancer cancer cells molecular pathology genomics histopathology breast oncology gastrointestinal oncology molecular medicine medicinal research cancer discovery malignant disease gene expression bioinformatics surgical pathology novel therapies thoracic oncology cancer letter melanoma sequence analysis next-generation sequencing cancer treatment medical virology medical mycology virus research antiviral research leukemia molecular gastroenterology hematological malignancies somatic variant skin cancer cancer risk molecular profiling high throughput sequencing tumor heterogeneity immune mediators innate immune system cytokines high-throughput screening mutation-based testing receptor tyrosine kinases cutaneous biology adaptive immune system antiviral responses cellular immune responses human pathology targeted therapy multiplex mutation screening infantile fibrosarcoma randomized controlled trials clinical infectious disease dna sequencing melanoma subtypes copy number advanced thoracic malignancies bacterial infections braf inhibitor dabrafenib whole exomic sequencing copy number alterations rapid cancer highly multiplexed pcr papillary neoplasms high prevalence adaptive immune responses

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 8: Using in Vitro Models to Predict Imatinib Responses in Pdgfra-Mutant Gastrointestinal Stromal Tumor.. Cancer Research (2026)

imatinib responsescancer researchabstract 8oncologyoncogenescancer cellsgastrointestinal oncologycancer biologypathologytumor biologycell biology

93 Sarcomas With Epc1/2:: Kdm2b Fusion: A Clinicopathologic and Molecular Study of 7 Cases Showing a Wide Morphologic Spectrum. Laboratory Investigation (2025)

molecular studytumoral pathologyanatomical pathologycancer researchmalignant diseasehistopathologywide morphologic spectrumsarcoma:kdm2b fusiononcogenessurgical pathologypathologymolecular pathologycell biology

Sarcoma Harbouring Cep170:: Rad51b Fusion: A Case Report Emphasizing Diagnostic Caution in Low‐Read, Pseudogene‐Associated Rearrangements. Histopathology (2025)

metastasisdiagnostic cautionanatomical pathologypathologymolecular diagnosticscancer researchsarcomacancer lettersurgical pathologycarcinogenesistumoral pathologyradiation oncologymalignant diseasecancer discoveryhistopathologymolecular biologyoncologycase reportmolecular pathology

Activity of Type II Raf Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel Snx8-Braf Gene Fusion. JCO Precision Oncology (2023)

malignant diseasenovel therapiespediatric patienttherapeutic targetsanti-cancer agentssarcomaoncogenic agentoncogenescancer treatmentcancer letterpathologycell biology

Appendix From Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer. (2023)

cancer geneticscancer caregeneticsurologypersonalized medicinecancer genomicsrelapse-free survivalbiostatisticsoncologymolecular diagnosticsoncogenescancer riskprostate cancerdetermine risk

Data From Combination Therapy for I Kit /I -Mutant Mast Cells: Targeting Constitutive Nfat and Kit Activity. (2023)

immunologygene therapysignaling pathwaysbiomedical researchkit activitycell signalingmolecular cancercell researchnovel therapiestherapeutic targets-mutant mast cellsoncogenescancer cellsmast cell disorderscombination therapytumor biologymolecular medicinecell biology

Legends for Supplemental Figures and Tables From Combination Therapy for I Kit /I -Mutant Mast Cells: Targeting Constitutive Nfat and Kit Activity. (2023)

immunologybiomedical researchsupplemental figureskit activitycell signalingbreast cancermast cell disorderscancer cellscombination therapycellular therapymolecular medicinecell biology

Molecular Profiling of Pre- and Post-Treatment Pediatric High-Grade Astrocytomas Reveals Acquired Increased Tumor Mutation Burden in a Subset of Recurrences. Acta Neuropathologica Communications (2023)

Matthew D. WoodCarol BeadlingTanaya NeffSteve MooreChristina A. HarringtonLissa BairdChristopher Corless

neurologygliomascancer biologycancer researchneuropathologymolecular profilingoncologyneuro-oncologypediatricsneuroscience

Supplemental Figure 1 From Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit a Variants of Unknown Significance. (2023)

biochemical geneticsenzymesmolecular metabolismalcohol dehydrogenasesmolecular biologybiological chemistrysupplemental figure 1clinical characterizationmetabolismunknown significancebiochemical sciencesmicrobiologybiochemistry

Supplementary Figure Legend From Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer. (2023)

cancer geneticscancer caremolecular cancerurologycancer genomicsprostatic diseasegenitourinary cancerssupplementary figure legendbiostatisticsoncologymolecular diagnosticsoncogenesrelapse-free survivalprostate cancerdetermine risk

1
2
3
4
5
8
10 / page

Carol Beadling

Oregon Health & Science University

Affiliations

OHSU School of Medicine

Department Of Medicine

Department Of Pediatrics

Department of Medicine

Division of Hematology & Medical Oncology

Department Of Medicine

Hematology and Medical Oncology

Department Of Pediatrics

Hematology and Oncology

Oregon Health & Science University

NoneCarol Beadling is currently serving as a Medicine faculty at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Carol Beadling

Oregon Health & Science University

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 8: Using in Vitro Models to Predict Imatinib Responses in Pdgfra-Mutant Gastrointestinal Stromal Tumor.. Cancer Research (2026)

imatinib responsescancer researchabstract 8oncologyoncogenescancer cellsgastrointestinal oncologycancer biologypathologytumor biologycell biology

93 Sarcomas With Epc1/2:: Kdm2b Fusion: A Clinicopathologic and Molecular Study of 7 Cases Showing a Wide Morphologic Spectrum. Laboratory Investigation (2025)

Sarcoma Harbouring Cep170:: Rad51b Fusion: A Case Report Emphasizing Diagnostic Caution in Low‐Read, Pseudogene‐Associated Rearrangements. Histopathology (2025)

Activity of Type II Raf Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel Snx8-Braf Gene Fusion. JCO Precision Oncology (2023)

malignant diseasenovel therapiespediatric patienttherapeutic targetsanti-cancer agentssarcomaoncogenic agentoncogenescancer treatmentcancer letterpathologycell biology

Appendix From Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer. (2023)

cancer geneticscancer caregeneticsurologypersonalized medicinecancer genomicsrelapse-free survivalbiostatisticsoncologymolecular diagnosticsoncogenescancer riskprostate cancerdetermine risk

Data From Combination Therapy for I Kit /I -Mutant Mast Cells: Targeting Constitutive Nfat and Kit Activity. (2023)

Legends for Supplemental Figures and Tables From Combination Therapy for I Kit /I -Mutant Mast Cells: Targeting Constitutive Nfat and Kit Activity. (2023)

immunologybiomedical researchsupplemental figureskit activitycell signalingbreast cancermast cell disorderscancer cellscombination therapycellular therapymolecular medicinecell biology

Matthew D. WoodCarol BeadlingTanaya NeffSteve MooreChristina A. HarringtonLissa BairdChristopher Corless

neurologygliomascancer biologycancer researchneuropathologymolecular profilingoncologyneuro-oncologypediatricsneuroscience

Supplemental Figure 1 From Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit a Variants of Unknown Significance. (2023)

Supplementary Figure Legend From Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer. (2023)

1
2
3
4
5
8
10 / page